Syndax Bags Second Asian Partner For Entinostat
This article was originally published in PharmAsia News
Executive Summary
Kyowa Hakko Kirin (KHK) has gained selected exclusive rights to Syndax's promising anticancer agent, marking the second Asian licensing deal for the oral histone deacetylase (HDAC) inhibitor.